Skip to content

Effects of Weight Loss on Vascular Function in Obese Subjects

Effects of Weight Loss on Vascular Function in Obese Individuals With Poor Cardiovascular Health

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04198519
Enrollment
50
Registered
2019-12-13
Start date
2019-11-21
Completion date
2023-11-20
Last updated
2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Obesity, Weight loss, Cardiovascular diseases, Sleep Apnea Syndromes, Arterial stiffness, Endothelial dysfunction

Brief summary

To evaluate the effect of weight loss on vascular function in obese with poor cardiovascular health. The investigators will evaluate the effects of weight loss on total and central body adiposity, blood pressure, central hemodynamic parameters, arterial stiffness, endothelial function, apnea-hypopnea index, insulin resistance and inflammatory markers.

Detailed description

Excessive adipose tissue is associated with adverse metabolic effects and is an important risk factor for chronic diseases. According to the American Heart Association, most cardiovascular events can be prevented by adhering to healthy practices, reflecting cardiovascular health as poor, intermediate, and ideal. Methods: Both sexes, aged between 40 and 70 years, with body mass index ≥ 30 and \< 40 kg/m² will be included and clinical, anthropometric, body composition and laboratory tests will be assessed. In vascular tests, the investigators will evaluate the sympathetic tone using a frequency meter (Polar® RS800), oscillometric pulse wave analysis by Mobil-O-Grah®, post-occlusive microvascular reactivity and carotid ultrasound to measure intimamedia thickness. In the sleep study, the investigators will analyze the presence and degree of obstructive sleep apnea (OSA) through the home polysomnography device (WatchPAT 200®). The first visit will be for screening, clinical and anthropometric evaluation. On the second visit, the vascular tests, instructions and device delivery for sleep study will be performed. Patients will return the following day to return the WatchPAT and to receive the hypocaloric nutritional intervention (800kcal reduction of daily total energy value), which should be followed for 16 weeks. Eight weeks after the beginning of the nutritional intervention a new visit will be scheduled for clinical, nutritional assessment and dietary adjustment. After completing 16 weeks, the patients will return for clinical, laboratory, nutritional, vascular and sleep tests.

Interventions

OTHERWeight Loss

The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.

Sponsors

Rio de Janeiro State Research Supporting Foundation (FAPERJ)
CollaboratorOTHER_GOV
Conselho Nacional de Desenvolvimento Científico e Tecnológico
CollaboratorOTHER_GOV
Mario Fritsch Neves
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

The participants do not know if they are classified as poor or intermediate/ideal cardiovascular health.

Intervention model description

Prospective

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients of both sexes; * Age between 40 and 70 years; * Body mass index (BMI) ≥ 30 kg/m² and \<40 kg/m².

Exclusion criteria

* Systolic blood pressure ≥ 160 and/or diastolic blood pressure ≥ 100 mmHg; * Diabetes mellitus; Hormone replacement therapy; * Evidence of secondary hypertension; * Clinically evident changes in thyroid function; * Acute or chronic kidney or liver disease; * History of cancer in the last 5 years; * Clinically evident coronary disease with a history of acute myocardial infarction and/or myocardial revascularization, clinical signs of heart failure, cardiac arrhythmia or clinically significant valve disease; * Previous stroke;

Design outcomes

Primary

MeasureTime frameDescription
Pulse wave velocityChange in PWV after 16-week dietary interventionPulse wave velocity (PWV) will be evaluated by oscillometric monitoring system via Mobil-O -Graph®

Secondary

MeasureTime frameDescription
Endothelial functionChange in endothelial function after 16-week dietary interventionMicrovascular reactivity will be evaluated using the laser system contrast image (LSCI)

Countries

Brazil

Contacts

Primary ContactMario F Neves, MD, PhD
mariofneves@gmail.com+55 21 28688005

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026